Q-omics provides the consensus-scored RPL34P17 profile across patient tissues and cancer cell-line models. RPL34P17 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, RPL34P17 is differentially expressed in 4, with the highest sampling consensus in STAD. Additionally, RPL34P17 RNA expression shows 13,828 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight CHOL, STAD, and GBM as cancer lineages where RPL34P17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL34P17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL34P17 survival associations across molecular data types. RPL34P17 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL34P17 RNA expression–survival associations across cancer types. High RPL34P17 expression shows unfavorable associations in HNSC, OV, MESO and TGCT, but favorable associations in CHOL and LUAD. The CHOL Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify CHOL as the clearest survival context for RPL34P17 RNA expression.
This table summarizes RPL34P17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL34P17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL34P17 shows lower tumor expression in THCA and higher tumor expression in STAD, LUAD and PRAD. The STAD box plot shows higher RPL34P17 RNA expression in tumor versus normal tissue (log2 FC = +0.223, t-test p = .020).
This table shows molecular features associated with RPL34P17 in patient tissues and cancer cell lines. In patient samples, RPL34P17 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
